Modulation of endothelial cell integrity and inflammatory activation by commercial lipid emulsions

Harvey, Kevin A; Xu, Zhidong; Pavlina, Thomas M; Zaloga, Gary P; Siddiqui, Rafat A

doi:10.1186/s12944-015-0005-6

Lipids in Health and Disease

Table 3 Fatty acid profile in SO-supplemented HAECs

From: Modulation of endothelial cell integrity and inflammatory activation by commercial lipid emulsions

Fatty acid	Vehicle	0.10%	1%	2%	5%	10%
8:0	0.41 ± 0.16	0.25 ± 0.07*	0.25 ± 0.05	0.28 ± 0.00	0.17 ± 0.02*	0.11 ± 0.00*
10:0	0.62 ± 0.28	0.43 ± 0.08	0.14 ± 0.01	0.48 ± 0.08	0.32 ± 0.01*	0.19 ± 0.05*
12:0	0.16 ± 0.05	0.19 ± 0.09	0.27 ± 0.04	0.24 ± 0.16	0.17 ± 0.01	0.11 ± 0.02
14:0	4.08 ± 0.85	3.75 ± 0.04	1.24 ± 0.06*	1.40 ± 0.08*	1.01 ± 0.04*	0.74 ± 0.10*
16:0	25.99 ± 4.34	25.07 ± 0.37	26.03 ± 1.38	24.05 ± 2.75	24.29 ± 0.32	24.30 ± 0.88
16:1n-7	4.16 ± 0.47	3.84 ± 0.04	1.05 ± 0.07*	1.96 ± 0.14*	1.55 ± 0.02*	1.49 ± 0.11*
18:0	16.94 ± 2.65	17.28 ± 0.25	13.89 ± 0.65	17.01 ± 1.76	15.34 ± 0.13	12.75 ± 0.69
18:1n-9	21.04 ± 3.08	20.60 ± 0.51	20.73 ± 1.11	20.64 ± 2.91	20.55 ± 0.22	20.13 ± 0.83
18:1n-7	8.34 ± 1.39	8.06 ± 0.18	2.43 ± 0.13*	4.23 ± 0.56*	3.43 ± 0.00*	2.59 ± 0.05*
18:2n-6	1.57 ± 0.24	2.08 ± 0.05	14.21 ± 0.85*	10.28 ± 1.97*	12.41 ± 0.75*	15.43 ± 0.52*
18:3n-6	0.16 ± 0.07	0.15 ± 0.01	0.82 ± 0.05*	0.44 ± 0.10*	0.68 ± 0.12*	1.12 ± 0.00*
18:3n-3	0.02 ± 0.01	0.01 ± 0.01	0.37 ± 0.03*	0.39 ± 0.09*	0.36 ± 0.00*	0.40 ± 0.02*
20:0	0.23 ± 0.04	0.20 ± 0.00	0.05 ± 0.01	0.25 ± 0.00	0.21 ± 0.01	0.17 ± 0.02
20:4n-6	10.22 ± 2.01	11.40 ± 0.25	10.81 ± 0.66	11.51 ± 1.36	11.96 ± 0.08	12.61 ± 0.37
20:5n-3	0.20 ± 0.04	0.20 ± 0.00	0.29 ± 0.03	0.16 ± 0.04	0.20 ± 0.02	0.24 ± 0.01
22:0	0.26 ± 0.05	0.22 ± 0.00	0.12 ± 0.01	0.22 ± 0.02	0.18 ± 0.01	0.14 ± 0.01*
22:5n-6	1.52 ± 0.38	1.78 ± 0.03	0.94 ± 0.04	1.19 ± 0.21	1.24 ± 0.02	1.22 ± 0.06
22:5n-3	1.62 ± 0.17	1.66 ± 0.09	1.06 ± 0.07	1.31 ± 0.24	1.10 ± 0.02*	0.84 ± 0.00*
24:0	0.43 ± 0.15	0.35 ± 0.02	0.12 ± 0.01	0.23 ± 0.06*	0.14 ± 0.02*	0.13 ± 0.01*
22:6n-3	1.91 ± 0.29	2.34 ± 0.06	5.18 ± 0.31*	4.05 ± 0.65*	4.98 ± 0.32*	5.68 ± 0.14*
SFA	49.11 ± 8.58	47.74 ± 0.94	42.11 ± 2.22	44.17 ± 4.91	41.85 ± 0.59	38.62 ± 1.77
MUFA	33.54 ± 4.93	32.50 ± 0.72	24.20 ± 1.31*	26.83 ± 3.61*	25.53 ± 0.25*	24.21 ± 0.99*
n-6 PUFA	13.46 ± 2.71	15.41 ± 0.33	26.33 ± 1.59*	23.42 ± 3.64*	26.30 ± 0.98*	30.38 ± 0.95*
n-3 PUFA	3.76 ± 0.50	4.22 ± 0.17	7.36 ± 0.45*	5.91 ± 1.02	6.63 ± 0.36	7.16 ± 0.18*
Total	99.87 ± 16.73	99.87 ± 2.17	100.00 ± 5.57	100.33 ± 13.18*	100.31 ± 2.18*	100.36 ± 3.89

HAECs were supplemented with varying doses of SO for 24 hours under standard tissue culture conditions prior to analysis. Total lipids were extracted as described in the methods. Quantification was based on the use of an internal standard and normalization to protein content. Results are expressed as the mean wt% ± SD of three determinants. *Denotes statistically significant differences (p ≤ 0.05) compared to vehicle control.

Back to article page

ISSN: 1476-511X

Contact us

General enquiries: journalsubmissions@springernature.com